Technology
Health
Pharmaceutical

Arcturus Therapeutics

$4.95
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.21 (-4.07%) Today
-$0.21 (-4.07%) Today

Why Robinhood?

You can buy or sell ARCT and other stocks, options, ETFs, and crypto commission-free!

About

Arcturus Therapeutics Ltd. engages in the provision of RNA medicines, which focuses on liver and respiratory diseases. Its RNA medicines include mRNA; siRNA, miRNA, and ASO;, CRISPR, TALEN, and meganucleases; and Replicon RNA and DNA. Read More The company was founded by Joseph Payne in March 2013 and is headquartered in San Diego, CA.

Employees
60
Headquarters
San Diego, California
Founded
2013
Market Cap
55.42M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
31.13K
High Today
$5.36
Low Today
$4.90
Open Price
$5.13
Volume
4.96K
52 Week High
$10.00
52 Week Low
$4.11

Collections

Technology
Health
Pharmaceutical
Therapy
Biopharmaceutical
2013 IPO
US
North America

News

Simply Wall StMar 8

Investors Who Bought Arcturus Therapeutics (NASDAQ:ARCT) Shares A Year Ago Are Now Down 18%

It’s easy to match the overall market return by buying an index fund. But if you buy individual stocks, you can do both better or worse than that. Investors in Arcturus Therapeutics Ltd. (NASDAQ:ARCT) have tasted that bitter downside in the last year, as the share price dropped 18%. That falls noticeably short of the market return of around 0.9%. Arcturus Therapeutics hasn’t been listed for long, so although we’re wary of recent listings that perform poorly, it may still prove itself with time. And the shar...

117
MarketBeatMar 8

Stock Price, News, & Analysis for Arcturus Therapeutics

Arcturus Therapeutics Ltd., an RNA medicines company, develops nucleic acid medicines to treat diseases with unmet medical needs. Its RNA therapeutics platforms could be applied in various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 120 p...

7

Earnings

Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
Actual
Expected Mar 18, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.